Modulation of left ventricular dilation remodeling with epicardial restraint devices in postmyocardial infarction

Veli K Topkara1, Srikanth Kondareddy, Douglas L Mann

  • 1Cardiovascular Division, Washington University School of Medicine, 660 South Euclid Avenue, Campus PO Box 8066, Saint Louis, MO 63110, USA.

Insights

Myocardial infarction causes harmful changes to the heart. This review explores epicardial restraint devices as a new treatment to reverse cardiac remodeling and improve outcomes after heart attack.

Area of Science:

  • Cardiology
  • Biomedical Engineering

Background:

  • Myocardial infarction triggers progressive cardiac remodeling, affecting myocytes and nonmyocytes.
  • Despite current treatments, heart failure remains a significant post-myocardial infarction complication with high mortality.
  • Left ventricular (LV) remodeling is a key driver of disease progression.

Purpose of the Study:

  • To review the emerging role of epicardial restraint devices.
  • To discuss their potential in treating post-myocardial cardiac remodeling.

Main Methods:

  • Literature review of studies on epicardial restraint devices.
  • Analysis of their impact on LV remodeling and clinical outcomes.

Main Results:

  • Epicardial restraint devices show promise in attenuating and potentially reversing LV remodeling.
  • These devices offer a novel therapeutic strategy beyond current evidence-based treatments.

Conclusions:

  • Epicardial restraint devices represent a promising innovation for managing post-myocardial infarction cardiac remodeling.
  • Further research is needed to establish their long-term efficacy and clinical utility.

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...